Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MITF | O75030 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | CBFB | Q13951 | 3/20 | 0.39 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
| ▸ | METAP1 | P53582 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6764632 | 0.81 | NPC1 (0.41) | NPC1KDM4EPKMRAB9AADORA3 | |
| Bromide SCHEMBL9368207 | 0.71 | TGFBR1 (0.43) | NPC1KDM4EMITFGAAPKM | |
| SCHEMBL6761705 | 0.70 | TGFBR1 (0.44) | NPC1KDM4EPKMRAB9ASMN1; SMN2 | |
| SCHEMBL13506384 | 0.69 | KDM4E (0.50) | NPC1KDM4EGAAPKMRAB9A | |
| SCHEMBL30229669 | 0.68 | NPC1 (0.59) | NPC1KDM4EMITFGAAPKM | |
| SCHEMBL30427456 | 0.68 | NPC1 (0.59) | NPC1KDM4EMITFGAAPKM | |
| SCHEMBL39129 | 0.68 | NPC1 (0.59) | NPC1KDM4EMITFGAAPKM | |
| SCHEMBL38663543 | 0.68 | CBFB (0.40) | NPC1KDM4EMITFGAAPKM | |
| SCHEMBL38662531 | 0.68 | MEN1 (0.43) | NPC1KDM4EGAAPKMRAB9A | |
| SCHEMBL38661790 | 0.68 | KDM4E (0.43) | NPC1KDM4EGAAPKMRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040220230-A1 | Pyridinylimidazoles | SMITHKLINE BEECHAM P.L.C. | 2004-11-04 | — | — | US | claimed |
| US-20030166633-A1 | Pyridinylimidazoles | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-09-04 | — | — | US | claimed |
| EP-1257543-A1 | PYRIDINYLIMIDAZOLES | SMITHKLINE BEECHAM PLC (GB) | 2002-11-20 | — | — | EP | claimed |
| WO-2001062756-A1 | PYRIDINYLIMIDAZOLES | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-08-30 | — | — | WO | claimed |
| US-20040220230-A1 | Pyridinylimidazoles | SMITHKLINE BEECHAM P.L.C. | 2004-11-04 | — | — | US | disclosed |
| US-20030166633-A1 | Pyridinylimidazoles | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-09-04 | — | — | US | disclosed |
| EP-1257543-A1 | PYRIDINYLIMIDAZOLES | SMITHKLINE BEECHAM PLC (GB) | 2002-11-20 | — | — | EP | disclosed |
| WO-2001062756-A1 | PYRIDINYLIMIDAZOLES | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166633-A1 | Pyridinylimidazoles | NR0B1, NR1I2, NR0B2 | NPC1 1966/4885KDM4E 3032/4885MITF 3725/4885 |
| US-20040220230-A1 | Pyridinylimidazoles | NR0B1, NR1I2, NR0B2 | NPC1 1327/4885KDM4E 3188/4885MITF 3508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.